Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy PF-06939926

Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy PF-06939926

NEW YORK–(BUSINESS WIRE)–October 01, 2020 — Pfizer Inc. (NYSE: PFE) today announce...
read more
Yale’s rapid COVID-19 saliva test receives FDA emergency use authorization

Yale’s rapid COVID-19 saliva test receives FDA emergency use authorization

A saliva-based laboratory diagnostic test develope...
read more